一般演題（口演）47 KRAS遺伝子変異陽性肺癌

[O47-2] Efficacy and safety of olomorasib plus pembrolizumab in KRAS G12C-mutant advanced NSCLC

^○Yutaka Fujiwara¹, Timothy F. Burns², Konstantin H. Dragnev³, Yonina R. Murciano-Goroff⁴, Dae Ho Lee⁵, Antoine Hollebecque⁶, Takafumi Koyama⁷, Philippe Cassier⁸, Antoine Italiano⁹, Rebecca S. Heist¹⁰, Ji-Youn Han¹¹, Dustin Deming¹², Alexander I. Spira¹³, Joshua K. Sabari¹⁴, Michael J. Chisamore¹⁵, Aaron Fink¹⁶, Aaron Chen¹⁶, Melinda D. Willard¹⁶, Geoffrey R. Oxnard¹⁶, Natraj Reddy Ammakkanavar¹⁷ (1.Aichi Cancer Center Hospital, Aichi, Japan, 2.Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA, 3.Department of Hematology/Oncology, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, 4.Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5.Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, 6.Gustave Roussy, Villejuif, France, 7.Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, 8.Department of Medical Oncology, Centre Léon Bérard, Lyon, France, 9.Early Phase Trials Unit, Institut Bergonié, Bordeaux, France, 10.Massachusetts General Hospital, Boston, MA, USA, 11.Research Institute, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea, 12.Carbone Cancer Center, University of Wisconsin, Madison, WI, USA, 13.Virginia Cancer Specialists, Fairfax, VA, USA, 14.NYU Langone Health – Perlmutter ＆ Long Island, New York, NY, USA, 15.Merck ＆ Co., Inc. Rahway, NJ, USA, 16.Loxo@Lilly, Stamford, CT, USA, 17.Community Health Network, Indianapolis, IN, USA)

アンコール演題